生物制剂与银屑病治疗
摘要
银屑病是一种T淋巴细胞介导的慢性炎症性疾病,致病的记忆-效应T淋巴细胞集聚于病变皮肤并产生Ⅰ型细胞因子是发病机制的中心环节。基于银屑病发病机制中细胞免疫的关键步骤,研究开发了一些具有靶位特异性的生物制剂,这类药物无特定脏器毒性,具有安全、易耐受和使用方便的特点,为银屑病的长期治疗提供了安全有效的方案。根据作用靶点,可将药物分为抑制抗原呈递和共刺激、抑制T淋巴细胞活化和白细胞结合、直接杀伤活化T淋巴细胞、抑制炎症介质的活性和调节细胞因子平衡5类。
出处
《世界临床药物》
CAS
2003年第8期462-466,共5页
World Clinical Drug
参考文献25
-
1Liberopoulos EN;Drosos AA;Elisaf MS.Exacerbation of tuberculosis enteritis after treatment with infliximab,2002(07).
-
2Schopf RE;Aust H;Knop J.Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha infliximab[J],2002(06).
-
3Gottlieb AB;Masud S;Ramamurthi R.Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris[J],2003(01).
-
4Krueger JG.The immunologic basis for the treatment of psoriasis with new biologic agents[J],2002(01).
-
5Gottlieb AB;Lebwohl M;Totoritis MC;etal.Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody[J],2002(05).
-
6Asadullah K;Volk HD;Friedrich M.Experimental therapies for psoriasis,2002(06).
-
7Schopf RE.IDEC-114 (IDEC),2001(05).
-
8Abrams JR;Kelley SL;Hayes E;etal.Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA41g) reverses the cellular pathology of psoriatic plaques including the activation of keratinocytes dendritic cells and endothelial cells,2000.
-
9Abrams JR;Lebwohl MG;Guzzo CA.CTLA41g-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris[J],1999(09).
-
10Najafian N;Sayegh MH.CTLA4-1g:a novel immunosuppressive agent[J],2000(09).
二级参考文献19
-
1[1]Luba KM,Stulberg DL.Chronic plaque psoriasis.Am Fam Physician,2006,73(4):636-644.
-
2[4]Krueger JG.The immunologic basis for the treatment of psoriasis with new biologic agents.J Am Acad Dermatal,2002,46(1):1-23.
-
3[5]Cball LA,Tso JY,Melrose J,et al.HuM291(Nuvion),a humanized Fc receptor-nonbinding antibody against CD3,anergizes peripheral blood T cells as partial agonist of the T cell receptor.Transplantation,2001,71(7):941-950.
-
4[6]Skov L,Kragballe K,Zachariae C,et al.HuMax-CD4:a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris.Arch Dermatol,2003,139(11):1433-1439.
-
5[7]Bachelez H,Flageul B,Dubertret L,et al.Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4.J Autoimmun,1998,11(1):53-62.
-
6[8]Gottlieb AB,Krueger JG,Wittkowski K,et al.Psoriasis as a model for T-cell-mediated disease:immunobiologic and clinical affects of treatment with multiple doses of efalizumab,an anti-CD11a antibody.Arch Dermatol,2002,1381(5):591-600.
-
7[9]Krueger JG,Waiters IB,Miyazawa M,et al.Successful in vivo blockade of CD25(high-affinity interleukin 2 receptor)on T cells by administration of humanized anti-Tac antibody to patients with psoriasis.J Am Acad Dermatol,2000,43(3):448-458.
-
8[10]da Silva AJ,Brickelmaier M,Majeau GR,et al.Alefacept,an immunomodulatory recombinant LFA-3/IgG1 fusion protein,induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+)cells.J Immunol,2002,168(9):4462-4471.
-
9[11]Ellis CN,Krueger GG.Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.N Engl J Med,2001,345(4):248-255.
-
10[13]Najafian N,Sayegh MH.CTLA4-Ig:a novel immanosuppressive agent.Expert Opin Investig Drugs,2000,9(9):2147-2157.
共引文献9
-
1郭涛,徐丽敏.T淋巴细胞与银屑病发病关系研究进展[J].山西中医,2009(5):60-62. 被引量:2
-
2赵艳霞.T淋巴细胞与银屑病发病机制的关系[J].中国中西医结合皮肤性病学杂志,2010,9(6):398-400. 被引量:17
-
3潘延斌,卢海,谭美乐,李建民.沙利度胺治疗银屑病的疗效及影响因素COX分析[J].中国误诊学杂志,2012,12(18):4857-4859.
-
4吴晖,王亚华,周金枝.血液灌流治疗银屑病规范性护理的作用分析[J].当代护士(中旬刊),2014,21(9):34-36.
-
5吉贤.李可乌蛇荣皮汤合攻毒散治疗寻常型银屑病30例疗效观察[J].新中医,2014,46(11):149-151. 被引量:2
-
6沈芳,谢韶琼.生物制剂治疗银屑病的机制及应用进展[J].医学综述,2015,21(11):2013-2016. 被引量:3
-
7楚瑞琦,刘平,谭升顺,彭振辉.银屑病的免疫生物学治疗进展[J].中华皮肤科杂志,2003,36(3):174-176. 被引量:10
-
8黄镜,徐兵河,蔡锐刚,储大同.基因重组人白细胞介素-11预防化疗所致血小板减少的临床效果[J].中国肿瘤临床,2003,30(4):258-260. 被引量:5
-
9刘萍,边强.治疗银屑病新药[J].世界临床药物,2003,24(8):507-508. 被引量:1
-
1陈英,智强,朱年春.重组人白细胞介素-10对银屑病患者外周血单个核细胞的作用[J].中国临床药理学与治疗学,2000,5(4):353-355.
-
2不良反应报道[J].世界临床药物,2006,27(7):387-389.
-
3张小娟,纪维,党文义,金汤.生物制剂治疗银屑病的进展[J].西北药学杂志,2007,22(3). 被引量:3
-
4陈执中.多发性硬化症治疗新药研究进展[J].药物生物技术,2009,16(2):186-188. 被引量:2
-
5齐继成(译).世界抗银屑病药物研究开发最新进展[J].中国制药信息,2008,24(1):3-6.
-
6杨娜.复方甘草甜素治疗寻常型银屑病临床疗效观察[J].菏泽医学专科学校学报,2005,17(4):12-12. 被引量:1
-
7罗恒.FDA批准地尼白介素-2治疗皮肤T细胞淋巴瘤[J].国外医药(抗生素分册),2009,30(1):44-45.
-
8艾克拜尔.安扎尔,热孜万.乌买尔.银屑病的T淋巴细胞介导免疫机制进展[J].内蒙古中医药,2011,30(1):85-86. 被引量:2
-
9刘晓霞,王雪玲,李振红,陈育民,陈剑华.八珍汤对人外周血T淋巴细胞体外增殖和活化的影响[J].生物医学工程学杂志,2010,27(4):855-858. 被引量:7
-
10陈飞虎,陈敏珠,李俊,智强.rhIL-10对银屑病动物模型的治疗作用及免疫功能的影响[J].中国药理学通报,2003,19(3):333-336. 被引量:7